Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00243)
Name
Eslicarbazepine acetate
Synonyms    Click to Show/Hide the Synonyms of This API
Eslicarbazepine acetate; 236395-14-5; BIA 2-093; Aptiom; Zebinix; Exalief; Stedesa; Erelib; Pazzul; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; SEP - 0002093; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; 5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-; Eslicarbazepine acetate (USAN); (10S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; (10S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; (S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Sep 0002093; BIA 2093; Zebinix (TN); Aptiom (TN); Eslicarbazapine Acetate; SCHEMBL250594; ZINC7295; DTXSID90178308; HMS3263M06; HMS3885N14; BIA-2093; HY-B0703; Tox21_501102; BDBM50240669; MFCD06798333; S-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; AKOS005145781; CCG-222406; DB09119; LP01102; SB18907; SDCCGSBI-0633789.P001; NCGC00165752-01; NCGC00165752-02; NCGC00165752-04; NCGC00165752-06; NCGC00261787-01; AC-31734; AS-14058; BIA 2-093, >=98% (HPLC), solid; D09612; J90004; AR-270/43507894; Q410273; J-015175; 10S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; 5-(aminocarbonyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; 5H-Dibenz9b,f)azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-; Acetic acid (S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl ester; Acetic acid 5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10(S)-yl ester
Clinical Status
Approved
Disease Indication Epilepsy ICD-11: 8A60 [1]
PubChem CID
179344
Formula
C17H16N2O3
Canonical SMILES
CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N
InChI
1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
InChIKey
QIALRBLEEWJACW-INIZCTEOSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=179344"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 296.32 Topological Polar Surface Area 72.6
XlogP 2 Complexity 440
Heavy Atom Count 22 Rotatable Bond Count 2
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Eslicarbazepine acetate 200 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Croscarmellose sodium; Povidone k30
                   Dosage Form Oral Tablet
                   Company Sunovion Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
          Eslicarbazepine acetate 400 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Croscarmellose sodium; Povidone k30
                   Dosage Form Oral Tablet
                   Company Sunovion Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
          Eslicarbazepine acetate 600 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Croscarmellose sodium; Povidone k30
                   Dosage Form Oral Tablet
                   Company Sunovion Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
          Eslicarbazepine acetate 800 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Croscarmellose sodium; Povidone k30
                   Dosage Form Oral Tablet
                   Company Sunovion Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
References
1 FDA label for approved eslicarbazepine acetate from the official website of the U.S. Food and Drug Administration.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.